Clinical Trials on Ectopic ACTH Secretion in Poland

Total 268 results

Pfizer

Active, not recruiting

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (JADE EXTEND)

Dermatitis, Atopic

China, United States, Spain, Taiwan, Germany, Australia, Canada, Hungary, Korea, Republic of, Poland, Serbia, Bulgaria, Czechia, Japan, Latvia, United Kingdom, Belgium, Israel, Italy, Finland, Mexico, Romania, Slovakia, Argentina, Brazil, Chil... and more
Regeneron Pharmaceuticals
Sanofi

Completed

Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)

Dermatitis, Atopic

United States, Germany, Poland, Canada, Czechia, United Kingdom
Almirall, S.A.

Completed

A Study of Lebrikizumab in Combination With Topical Corticosteroids in Participants Having Atopic Dermatitis (AD) That Are Not Adequately Controlled or Non-eligible for Cyclosporine

Eczema | Dermatitis, Atopic

Austria, Belgium, France, Germany, Netherlands, Poland, Spain, United Kingdom
Sanofi

Recruiting

Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD)

Dermatitis Atopic

Norway, Spain, Argentina, Israel, Greece, United States, Australia, Brazil, Canada, China, Colombia, Denmark, France, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Portugal, Russian Federation
GlaxoSmithKline

Completed

Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis

Dermatitis, Atopic

United States, Canada
Sun Pharmaceutical Industries Limited

Recruiting

To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis (SOLARES-AD-1)

Dermatitis, Atopic

United States, El Salvador
Vyne Therapeutics Inc.

Terminated

Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)

Psoriasis | Pruritus | Atopic Dermatitis | Prurigo Nodularis

United States, Austria, Germany, Poland
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis (SOLO 2)

Dermatitis, Atopic

United States, France, Poland, United Kingdom, Germany, Hong Kong, Canada, Korea, Republic of, Italy, Lithuania, Sweden
Nektar Therapeutics
Eli Lilly and Company

Completed

A Study of LY3471851 in Participants With Eczema

Dermatitis, Atopic

United States
Merck Sharp & Dohme LLC

Completed

Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)

Dermatitis, Atopic

United States, Belgium, Bulgaria, Canada, Romania, Spain
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD) (PROSE)

Dermatitis, Atopic

United States, Canada
GlaxoSmithKline

Recruiting

A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis

Dermatitis, Atopic

Spain, Bulgaria, Germany, Korea, Republic of, Canada, Argentina, China, United States, Poland, Italy, Czechia, Japan, Panama, Greece, Thailand, France, Mexico
GlaxoSmithKline

Not yet recruiting

Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis. (AtDvance)

Dermatitis, Atopic

United States, Germany, Spain, France, Italy, Japan, China, Argentina, Greece, Czechia, Korea, Republic of, Panama, Bulgaria, Canada, Poland, Mexico, Thailand
Pfizer

Completed

Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects

Skin Diseases | Immune System Diseases | Hypersensitivity | Hypersensitivity, Immediate | Genetic Diseases, Inborn | Skin Diseases, Genetic | Dermatitis | Eczema | Skin Diseases, Eczematous | Dermatitis, Atopic

United States, Spain, Taiwan, Germany, Canada, China, Poland, Belgium, Serbia, Brazil, Russian Federation, Israel, Latvia, Italy, Romania, Mexico, Argentina, Bulgaria, Chile, Netherlands, Slovakia
Pfizer

Completed

Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy (JADE Compare)

Skin Diseases | Immune System Diseases | Hypersensitivity | Hypersensitivity, Immediate | Genetic Diseases, Inborn | Skin Diseases, Genetic | Dermatitis | Eczema | Skin Diseases, Eczematous | Dermatitis, Atopic

Spain, Taiwan, United States, Australia, Poland, Germany, Hungary, Bulgaria, Czechia, Japan, Korea, Republic of, Latvia, Canada, United Kingdom, Mexico, Chile, Slovakia, Italy
Galderma R&D

Completed

A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab

Dermatitis, Atopic

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis (SOLO 1)

Dermatitis, Atopic

United States, Germany, Spain, Bulgaria, Japan, Canada, Denmark, Finland, Singapore, Estonia
Target PharmaSolutions, Inc.

Recruiting

A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC (TARGET-DERM)

Psoriasis | Atopic Dermatitis | Vitiligo | Hidradenitis Suppurativa | Alopecia Areata | Chronic Spontaneous Urticaria

United States, Spain, Canada, Germany

Clinical Trials on Ectopic ACTH Secretion in Poland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations